|
ACE Arthritis Medications Report Card Where does your province rank? Advanced therapies such as biologics (originator and biosimilar) and targeted small molecule medications, deliver value both medically and socially. Used in a timely and appropriate fashion, these medications are life-changing; in some cases, life-saving. However, patients with inflammatory arthritis still have unmet medication needs. The gaps in treatment are a reflection of the fact that inflammatory arthritis is a complicated disease. It is a disease driven by many different biologic processes, so no single treatment is effective for every patient. In fact, a significant number of patients do not respond well or well enough to their initial, or second or third trialed, which underlines the need for continued discovery of other therapeutic targets. Public drug plan policies at both the national, provincial, and territorial government levels are changing reimbursement access to treatment options for Canadians living with an inflammatory arthritis. The Arthritis Consumer Experts (ACE) Arthritis Medications Report Card is designed to help Canadians evaluate where their province ranks in terms of providing reimbursement for medications approved for inflammatory arthritis such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis. The ACE Arthritis Medications Report Card tracks advanced therapy disease modifying anti-rheumatic drugs (or DMARDs) used to treat the most common types of inflammatory arthritis:
|
||||||||
| 1st : Ontario (Last year: 1st) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | No Info | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | No Info | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 2nd : Québec (Last year: 2nd) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Listed—CBC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Listed—CBC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Listed—CBC | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 3rd : New Brunswick (Last year: 6th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Declined | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 4th : Manitoba (Last year: 6th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | No Info | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | No Info | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 4th : Nova Scotia (Last year: 6th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 4th : Saskatchewan (Last year: 5th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | No Info | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 7th : Alberta (Last year :3rd) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | No Info | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | No Info | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No Info |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 8th : Newfoundland and Labrador (Last year: 9th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Under Review | Under Review | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 8th : NIHB* (Last year: 11th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Declined | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | No NOC | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 10th : Prince Edward Island (Last year: 10th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Under Review | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| 11th : British Columbia (Last year: 3rd) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | No Info | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Declined | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Declined | Under Review | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| 12th : Northwest Territories N/A | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Listed—CBC | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | No Info | Not Reimbursed | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Declined | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| sarilumab (Kevzara®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Declined | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Under Review | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| 13th : Yukon (Last year: 12th) | ||||||||
| generic name (Brand Name) | rheumatoid arthritis | axial spondyloarthritis | juvenile arthritis | psoriatic arthritis | lupus | vasculitis | osteoporosis | |
| ankylosing spondylitis | non-radiographic axial spondyloarthritis (not visible on X-ray) | |||||||
| abatacept (Orencia®) | Listed—CBC | No NOC | No NOC | Under Review | Under Review | No NOC | No NOC | No NOC |
| adalimumab (Humira®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| adalimumab (Abrilada®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Amgevita®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hadlima®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hulio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Hyrimoz®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Idacio®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Simlandi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| adalimumab (Yuflyma®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| anakinra (Kineret®) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| anifrolumab (Saphnelo®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| belimumab (Benlysta®) | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC |
| bimekizumab (Bimzelx®) | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| canakinumab (Ilaris®) | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC | No NOC |
| certolizumab pegol (Cimzia®) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| denosumab (Prolia®, boDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC |
| denosumab (Jubbonti®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| etanercept (Enbrel®, boDMARD) | Not Reimbursed | Not Reimbursed | No NOC | Not Reimbursed | Not Reimbursed | No NOC | No NOC | No NOC |
| etanercept (Brenzys®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Erelzi®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | Listed—CBC | Listed—CBC | No NOC | No NOC | No NOC |
| etanercept (Rymti®, bsDMARD) | No Info | No Info | No NOC | No Info | No Info | No NOC | No NOC | No NOC |
| golimumab (Simponi®) | Listed—CBC | Listed—CBC | Under Review | No Info | Listed—CBC | No NOC | No NOC | No NOC |
| guselkumab (Tremfya®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| infliximab (Remicade®, boDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Avsola®, bsDMARD) | Under Review | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| infliximab (Inflectra®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Renflexis®, bsDMARD) | Listed—CBC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| infliximab (Remsima®, bsDMARD) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| ixekizumab (Taltz®) | No NOC | Under Review | No Info | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| rituximab (Rituxan®, boDMARD) | Not Reimbursed | No NOC | No NOC | No NOC | No NOC | No NOC | Not Reimbursed | No NOC |
| rituximab (Riximyo®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Ruxience®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| rituximab (Truxima®, bsDMARD) | Listed—CBC | No NOC | No NOC | No NOC | No NOC | No NOC | Listed—CBC | No NOC |
| romosozumab (Evenity®) | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | Under Review |
| sarilumab (Kevzara®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
| secukinumab (Cosentyx®) | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | No NOC |
| tocilizumab (Actemra®, boDMARD) | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC | No NOC | Listed—CBC | No NOC |
| tocilizumab (Tyenne®, bsDMARD) | Under Review | No NOC | No NOC | Under Review | No NOC | No NOC | Under Review | No NOC |
| ustekinumab (Stelara®, boDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Jamteki®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
| ustekinumab (Steqeyma®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| ustekinumab (Wezlana®, bsDMARD) | No NOC | No NOC | No NOC | No NOC | No Info | No NOC | No NOC | No NOC |
|
apremilast (Otezla®)
Auro-Apremilast, Jamp Apremilast, Sandoz Apremilast |
No NOC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| baricitinib (Olumiant®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
|
tofacitinib (Xeljanz®)
Auro-tofacitinib, Jamp tofacitinib, PMS-tofacitinib, Taro-tofacitinib |
Listed—CBC | No NOC | No NOC | No NOC | Under Review | No NOC | No NOC | No NOC |
| upadacitinib (Rinvoq®) | Under Review | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC | No NOC |
About the report card:
Arthritis Consumer Experts graded each of the provinces by assigning a score based upon number of medications listed, number under review, and number of declined listings. Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.
Definitions
| Listed—CBC: | The medication is listed on the public drug plan and may be considered for reimbursement on a case-by-case basis. |
| Listed—ORC: | The medication is listed for reimbursement on the public drug plan, but the reimbursement criteria are not aligned with current treatment guidelines developed by the clinical experts in the field. |
| Under Review: | The medication has been issued a Notice of Compliance (NOC) by Health Canada. The medication is either under a review by the Canadian Drug Agency or public drug plan for reimbursement listing that includes the assessment of the scientific, clinical evidence and patient perspective, as well as the impact on health services as compared to existing treatments. |
| Declined: | After a review, the public drug plan has declined the medication for reimbursement listing. |
| Not reimbursed: | The medication is no longer reimbursed by the public drug plan. |
| No NOC: | The medication has not been issued a Notice of Compliance (NOC) from Health Canada that authorizes a manufacturer to sell a medication in Canada. |
Learn more: The medication review process in Canada is complex and designed to ensure that pharmaceutical manufacturers bring their new medications to market in a safe, effective, and cost-effective manner. Click here to view Arthritis Consumer Experts’ special report – From discovery to the patient: The long and winding road towards drug development, review, and public reimbursement in Canada.
* Note: The Non-Insured Health Benefits (NHIB) program provides supplementary health benefits, including prescription and non-prescription drugs, for registered First Nations and recognized Inuit throughout Canada.
Disclaimer: The material contained in this or any other ACE publication is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. If you have any healthcare related questions or concerns, you should contact your physician. Never disregard medical advice or delay in seeking it because of something you have read in any ACE publication.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.